The purpose of this trial is to explore the effect of LY2127399 on those antibodies that are a barrier to kidney transplant. Transplantation is currently the definitive treatment for End-Stage Renal Disease (ESRD), providing prolonged survival and improved quality of life.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change From Baseline in PRA
Timeframe: Baseline, Weeks 8, 16, 24, 36, 52, 64 and 76
Change From Baseline in Arcsine Transformed PRA Scores
Timeframe: Baseline, Weeks 8, 16, 24, 36, 52, 64 and 76
Number of Participants With a Change From Baseline Positive to Post-Baseline Negative in the Summation of Top 10 Highest Antibody Levels (Class I and Class II Single Antigen Reactivity Reported Separately) During Treatment and Follow-Up
Timeframe: Baseline through Weeks 24, 52 and 76